Ma B et al. |
Strontium fructose 1,6-diphosphate prevents bone loss in a rat model of postmenopausal osteoporosis via the OPG/RANKL/RANK pathway. |
2012 |
Acta Pharmacol. Sin. |
pmid:22426695
|
Mirzaei K et al. |
Potential role of OPG/RANKL system and FokI genotypes in pathogenesis and clinical manifestations in multiple sclerosis. |
2012 |
Minerva Med. |
pmid:22805623
|
Terpos E et al. |
Early effects of IL-6 receptor inhibition on bone homeostasis: a pilot study in women with rheumatoid arthritis. |
2011 Nov-Dec |
Clin. Exp. Rheumatol. |
pmid:22032557
|
Arikan F et al. |
C-telopeptide pyridinoline crosslinks of type I collagen, soluble RANKL, and osteoprotegerin levels in crevicular fluid of dental implants with peri-implantitis: a case-control study. |
2011 Mar-Apr |
Int J Oral Maxillofac Implants |
pmid:21483881
|
Crespi R et al. |
Corticocancellous porcine bone in the healing of human extraction sockets: combining histomorphometry with osteoblast gene expression profiles in vivo. |
2011 Jul-Aug |
Int J Oral Maxillofac Implants |
pmid:21841997
|
Franke S et al. |
Advanced glycation end products affect growth and function of osteoblasts. |
2011 Jul-Aug |
Clin. Exp. Rheumatol. |
pmid:21906430
|
Rezg R et al. |
Inhibitors of vascular calcification as potential therapeutic targets. |
2011 Jul-Aug |
J. Nephrol. |
pmid:21688249
|
Reyes-GarcÃa R et al. |
[Cardiovascular disease and bone metabolism]. |
2011 Aug-Sep |
Endocrinol Nutr |
pmid:21775224
|
Gurban CV and Mederle O |
The OPG/RANKL system and zinc ions are promoters of bone remodeling by osteoblast proliferation in postmenopausal osteoporosis. |
2011 |
Rom J Morphol Embryol |
pmid:22119834
|
Ostrowska Z et al. |
Circadian concentrations of free testosterone, selected markers of bone metabolism, osteoprotegerin and its ligand sRANKL in obese postmenopausal women. |
2011 |
Postepy Hig Med Dosw (Online) |
pmid:22100799
|
Kurabayashi M |
[Bone and calcium update; diagnosis and therapy of bone metabolism disease update. Calcification of atherosclerotic plaques: mechanism and clinical significance]. |
2011 |
Clin Calcium |
pmid:22133823
|
Gordon IK and Camphausen K |
Research highlights. |
2011 |
Biomark Med |
pmid:21861664
|
Sood SK et al. |
Osteoprotegerin (OPG) and related proteins (RANK, RANKL and TRAIL) in thyroid disease. |
2011 |
World J Surg |
pmid:21748518
|
Stein SH and Tipton DA |
Vitamin D and its impact on oral health--an update. |
2011 |
J Tenn Dent Assoc |
pmid:21748977
|
Xie H et al. |
Omentin-1 attenuates arterial calcification and bone loss in osteoprotegerin-deficient mice by inhibition of RANKL expression. |
2011 |
Cardiovasc. Res. |
pmid:21750093
|
Wang Y et al. |
Alendronate (ALN) combined with osteoprotegerin (OPG) significantly improves mechanical properties of long bone than the single use of ALN or OPG in the ovariectomized rats. |
2011 |
J Orthop Surg Res |
pmid:21752290
|
Plasilova M et al. |
Discordant gene expression signatures and related phenotypic differences in lamin A- and A/C-related Hutchinson-Gilford progeria syndrome (HGPS). |
2011 |
PLoS ONE |
pmid:21738662
|
Ren G et al. |
Simultaneous administration of fluoride and selenite regulates proliferation and apoptosis in murine osteoblast-like MC3T3-E1 cells by altering osteoprotegerin. |
2011 |
Biol Trace Elem Res |
pmid:21739163
|
Sylvester FA et al. |
Fecal osteoprotegerin may guide the introduction of second-line therapy in hospitalized children with ulcerative colitis. |
2011 |
Inflamm. Bowel Dis. |
pmid:21744427
|
Lossdörfer S et al. |
PTH(1-34)-induced changes in RANKL and OPG expression by human PDL cells modify osteoclast biology in a co-culture model with RAW 264.7 cells. |
2011 |
Clin Oral Investig |
pmid:20697756
|
Tipton DA et al. |
Effect of bisphosphonates on human gingival fibroblast production of mediators of osteoclastogenesis: RANKL, osteoprotegerin and interleukin-6. |
2011 |
J. Periodont. Res. |
pmid:20701670
|
Nakamura M and Udagawa N |
[Osteoporosis and RANKL signal]. |
2011 |
Clin Calcium |
pmid:21814019
|
Persson E and Lerner UH |
The neuropeptide VIP regulates the expression of osteoclastogenic factors in osteoblasts. |
2011 |
J. Cell. Biochem. |
pmid:21815197
|
Üstündağ M et al. |
The role of serum osteoprotegerin and S-100 protein levels in patients with acute ischaemic stroke: determination of stroke subtype, severity and mortality. |
2011 |
J. Int. Med. Res. |
pmid:21819709
|
Bellido M et al. |
Improving subchondral bone integrity reduces progression of cartilage damage in experimental osteoarthritis preceded by osteoporosis. |
2011 |
Osteoarthr. Cartil. |
pmid:21820069
|
Lawrie A et al. |
Paigen diet-fed apolipoprotein E knockout mice develop severe pulmonary hypertension in an interleukin-1-dependent manner. |
2011 |
Am. J. Pathol. |
pmid:21835155
|
Poulsen MK et al. |
Plasma osteoprotegerin is related to carotid and peripheral arterial disease, but not to myocardial ischemia in type 2 diabetes mellitus. |
2011 |
Cardiovasc Diabetol |
pmid:21838881
|
Markatseli AE et al. |
Association of the A1330V and V667M polymorphisms of LRP5 with bone mineral density in Greek peri- and postmenopausal women. |
2011 |
Maturitas |
pmid:21840657
|
Kauther MD et al. |
Calcitonin substitution in calcitonin deficiency reduces particle-induced osteolysis. |
2011 |
BMC Musculoskelet Disord |
pmid:21843355
|
Sudrová M et al. |
Influence of long-term thromboprophylaxis with low-molecular-weight heparin (enoxaparin) on changes of bone metabolism markers in pregnant women. |
2011 |
Clin. Appl. Thromb. Hemost. |
pmid:20682598
|
Mamalis AA et al. |
Chemical modification of an implant surface increases osteogenesis and simultaneously reduces osteoclastogenesis: an in vitro study. |
2011 |
Clin Oral Implants Res |
pmid:21070383
|
Vitoratos N et al. |
Maternal circulating osteoprotegerin and soluble RANKL in pre-eclamptic women. |
2011 |
Eur. J. Obstet. Gynecol. Reprod. Biol. |
pmid:21074311
|
Belibasakis GN et al. |
Oral biofilm challenge regulates the RANKL-OPG system in periodontal ligament and dental pulp cells. |
2011 |
Microb. Pathog. |
pmid:21075196
|
Wattanaroonwong N et al. |
Oestrogen inhibits osteoclast formation induced by periodontal ligament fibroblasts. |
2011 |
Arch. Oral Biol. |
pmid:21035111
|
Nybo M et al. |
Rosiglitazone decreases plasma levels of osteoprotegerin in a randomized clinical trial with type 2 diabetes patients. |
2011 |
Basic Clin. Pharmacol. Toxicol. |
pmid:21726411
|
Fradet A et al. |
Dual function of ERRα in breast cancer and bone metastasis formation: implication of VEGF and osteoprotegerin. |
2011 |
Cancer Res. |
pmid:21734015
|
Kaneko K and Kawai S |
[Mechanisms and therapeutics of glucocorticoid-induced osteoporosis]. |
2011 |
Nihon Rinsho Meneki Gakkai Kaishi |
pmid:21720102
|
Zhang Y et al. |
Study of the mechanisms by which Sambucus williamsii HANCE extract exert protective effects against ovariectomy-induced osteoporosis in vivo. |
2011 |
Osteoporos Int |
pmid:20414641
|
Conaway HH et al. |
Retinoids stimulate periosteal bone resorption by enhancing the protein RANKL, a response inhibited by monomeric glucocorticoid receptor. |
2011 |
J. Biol. Chem. |
pmid:21715325
|
Hie M and Tsukamoto I |
Vitamin C-deficiency stimulates osteoclastogenesis with an increase in RANK expression. |
2011 |
J. Nutr. Biochem. |
pmid:20444587
|
El-Shehaby A et al. |
Correlations of urinary biomarkers, TNF-like weak inducer of apoptosis (TWEAK), osteoprotegerin (OPG), monocyte chemoattractant protein-1 (MCP-1), and IL-8 with lupus nephritis. |
2011 |
J. Clin. Immunol. |
pmid:21691937
|
Nich C et al. |
Oestrogen deficiency modulates particle-induced osteolysis. |
2011 |
Arthritis Res. Ther. |
pmid:21696618
|
Belibasakis GN et al. |
Porphyromonas gingivalis induces RANKL in T-cells. |
2011 |
Inflammation |
pmid:20446027
|
Clézardin P |
[The role of RANK/RANKL/osteoprotegerin (OPG) triad in cancer-induced bone diseases: physiopathology and clinical implications]. |
2011 |
Bull Cancer |
pmid:21700551
|
Celczyńska Bajew L et al. |
The effects of osteoprotegerin (OPG) gene polymorphism in patients with ischaemic heart disease on the morphology of coronary arteries and bone mineral density. |
2011 |
Kardiol Pol |
pmid:21678294
|
Dzida G |
[Decalcified bones, calcified heart?]. |
2011 |
Kardiol Pol |
pmid:21678295
|
Yang Q et al. |
Plasma osteoprotegerin levels and long-term prognosis in patients with intermediate coronary artery lesions. |
2011 |
Clin Cardiol |
pmid:21678453
|
Toffoli B et al. |
Osteoprotegerin promotes vascular fibrosis via a TGF-β1 autocrine loop. |
2011 |
Atherosclerosis |
pmid:21679949
|
de Moraes M et al. |
Comparative immunohistochemical expression of RANK, RANKL and OPG in radicular and dentigerous cysts. |
2011 |
Arch. Oral Biol. |
pmid:21683340
|
Ndip A et al. |
The RANKL/RANK/OPG signaling pathway mediates medial arterial calcification in diabetic Charcot neuroarthropathy. |
2011 |
Diabetes |
pmid:21659498
|
Roshandel D et al. |
Influence of polymorphisms in the RANKL/RANK/OPG signaling pathway on volumetric bone mineral density and bone geometry at the forearm in men. |
2011 |
Calcif. Tissue Int. |
pmid:21964949
|
Davenport C et al. |
Identifying coronary artery disease in men with type 2 diabetes: osteoprotegerin, pulse wave velocity, and other biomarkers of cardiovascular risk. |
2011 |
J. Hypertens. |
pmid:21970938
|
Miyamoto K et al. |
Osteoclasts are dispensable for hematopoietic stem cell maintenance and mobilization. |
2011 |
J. Exp. Med. |
pmid:22006978
|
Quemerais-Durieu MA et al. |
[Therapeutic innovation in osteoporosis (antisclerostin antibody and denosumab)]. |
2011 |
Ann. Endocrinol. (Paris) |
pmid:22008272
|
Koo HM et al. |
Elevated osteoprotegerin is associated with inflammation, malnutrition and new onset cardiovascular events in peritoneal dialysis patients. |
2011 |
Atherosclerosis |
pmid:22015178
|
Cao H et al. |
Dysregulated atrial gene expression of osteoprotegerin/receptor activator of nuclear factor-κB (RANK)/RANK ligand axis in the development and progression of atrial fibrillation. |
2011 |
Circ. J. |
pmid:22001292
|
Scialla JJ et al. |
Correlates of osteoprotegerin and association with aortic pulse wave velocity in patients with chronic kidney disease. |
2011 |
Clin J Am Soc Nephrol |
pmid:21940840
|
Sfiridaki K et al. |
Angiogenesis-related cytokines, RANKL, and osteoprotegerin in multiple myeloma patients in relation to clinical features and response to treatment. |
2011 |
Mediators Inflamm. |
pmid:21941412
|
Bao L et al. |
Anthraquinone compounds from Morinda officinalis inhibit osteoclastic bone resorption in vitro. |
2011 |
Chem. Biol. Interact. |
pmid:21945525
|
Cianciolo G et al. |
Effects of unfractioned heparin and low-molecular-weight heparin on osteoprotegerin and RANKL plasma levels in haemodialysis patients. |
2011 |
Nephrol. Dial. Transplant. |
pmid:20659908
|
Duheron V et al. |
Receptor activator of NF-kappaB (RANK) stimulates the proliferation of epithelial cells of the epidermo-pilosebaceous unit. |
2011 |
Proc. Natl. Acad. Sci. U.S.A. |
pmid:21402940
|
Dimitrow PP et al. |
The influence of statins on levels of calcification biomarkers in patients with aortic sclerosis or mild aortic stenosis. |
2011 |
J. Heart Valve Dis. |
pmid:21404893
|
Marques EA et al. |
Effects of resistance and aerobic exercise on physical function, bone mineral density, OPG and RANKL in older women. |
2011 |
Exp. Gerontol. |
pmid:21316442
|
Chin A et al. |
Effects of medicinal herb salvia miltiorrhiza on osteoblastic cells in vitro. |
2011 |
J. Orthop. Res. |
pmid:21319217
|
Mencej-BedraÄ S et al. |
TNFRSF11B gene polymorphisms 1181G > C and 245T > G as well as haplotype CT influence bone mineral density in postmenopausal women. |
2011 |
Maturitas |
pmid:21411255
|
Lee JC et al. |
Role of RANK-RANKL-OPG axis in cranial suture homeostasis. |
2011 |
J Craniofac Surg |
pmid:21415639
|
Goto H et al. |
Human bone marrow adipocytes support dexamethasone-induced osteoclast differentiation and function through RANKL expression. |
2011 |
Biomed. Res. |
pmid:21383509
|
Belibasakis GN et al. |
The RANKL-OPG system is differentially regulated by supragingival and subgingival biofilm supernatants. |
2011 |
Cytokine |
pmid:21474331
|
Mainini G et al. |
Serum osteoprotegerin correlates with age and bone mass in postmenopausal, but not in fertile age women. |
2011 |
Clin Exp Obstet Gynecol |
pmid:22268274
|
Riksen EA et al. |
Human osteoblastic cells discriminate between 20-kDa amelogenin isoforms. |
2011 |
Eur. J. Oral Sci. |
pmid:22243268
|
Yang Z et al. |
[Effects of negative pressure on osteogenesis in human bone marrow-derived stroma cells cultured in vitro]. |
2011 |
Zhongguo Gu Shang |
pmid:22276514
|
Hall J et al. |
A controlled clinical exploratory study on genetic markers for peri-implantitis. |
2011 |
Eur J Oral Implantol |
pmid:22282733
|
Stein SH et al. |
Statins regulate interleukin-1β-induced RANKL and osteoprotegerin production by human gingival fibroblasts. |
2011 |
J. Periodont. Res. |
pmid:21463327
|
Liang QQ et al. |
The expression of osteoprotegerin is required for maintaining the intervertebral disc endplate of aged mice. |
2011 |
Bone |
pmid:21466864
|
Honda K |
Interleukin-6 and soluble interleukin-6 receptor suppress osteoclastic differentiation by inducing PGE(2) production in chondrocytes. |
2011 |
J Oral Sci |
pmid:21467819
|
Moldenhauer A et al. |
Interleukin 32 promotes hematopoietic progenitor expansion and attenuates bone marrow cytotoxicity. |
2011 |
Eur. J. Immunol. |
pmid:21469100
|
Kim H et al. |
Association between Wnt signaling pathway gene polymorphisms and bone response to hormone therapy in postmenopausal Korean women. |
2011 |
Menopause |
pmid:21471826
|
Mulcahy LE et al. |
RANKL and OPG activity is regulated by injury size in networks of osteocyte-like cells. |
2011 |
Bone |
pmid:20854946
|
Aspenberg P et al. |
Targeting RANKL for reduction of bone loss around unstable implants: OPG-Fc compared to alendronate in a model for mechanically induced loosening. |
2011 |
Bone |
pmid:20858557
|
Kurnatowska I et al. |
Serum osteoprotegerin is a predictor of progression of atherosclerosis and coronary calcification in hemodialysis patients. |
2011 |
Nephron Clin Pract |
pmid:20861651
|
de Souza Faloni AP et al. |
Jaw and long bone marrows have a different osteoclastogenic potential. |
2011 |
Calcif. Tissue Int. |
pmid:20862464
|
Dimitri P et al. |
Adipokines, bone-derived factors and bone turnover in obese children; evidence for altered fat-bone signalling resulting in reduced bone mass. |
2011 |
Bone |
pmid:20932948
|
Yu H et al. |
Overexpression of osteoprotegerin promotes preosteoblast differentiation to mature osteoblasts. |
2011 |
Angle Orthod |
pmid:20936961
|
Palaniswamy C et al. |
Association of warfarin use with valvular and vascular calcification: a review. |
2011 |
Clin Cardiol |
pmid:21298649
|
Bostanci N et al. |
Effect of periodontal treatment on receptor activator of NF-κB ligand and osteoprotegerin levels and relative ratio in gingival crevicular fluid. |
2011 |
J. Clin. Periodontol. |
pmid:21261673
|
Andersen GØ et al. |
Elevated serum osteoprotegerin levels measured early after acute ST-elevation myocardial infarction predict final infarct size. |
2011 |
Heart |
pmid:21270073
|
Tsukamoto S et al. |
Clinical significance of osteoprotegerin expression in human colorectal cancer. |
2011 |
Clin. Cancer Res. |
pmid:21270110
|
Monnouchi S et al. |
The roles of angiotensin II in stretched periodontal ligament cells. |
2011 |
J. Dent. Res. |
pmid:21270461
|
Chang YH et al. |
Serum osteoprotegerin and tumor necrosis factor related apoptosis inducing-ligand (TRAIL) are elevated in type 2 diabetic patients with albuminuria and serum osteoprotegerin is independently associated with the severity of diabetic nephropathy. |
2011 |
Metab. Clin. Exp. |
pmid:21251686
|
Benslimane-Ahmim Z et al. |
Osteoprotegerin, a new actor in vasculogenesis, stimulates endothelial colony-forming cells properties. |
2011 |
J. Thromb. Haemost. |
pmid:21255246
|
Bai P et al. |
Disturbance of the OPG/RANK/RANKL pathway and systemic inflammation in COPD patients with emphysema and osteoporosis. |
2011 |
Respir. Res. |
pmid:22176920
|
Piedra M et al. |
"Single nucleotide polymorphisms of the OPG/RANKL system genes in primary hyperparathyroidism and their relationship with bone mineral density". |
2011 |
BMC Med. Genet. |
pmid:22185226
|
Kawaguchi H |
[Approach for therapeutic targets of osteoarthritis]. |
2011 |
Nippon Yakurigaku Zasshi |
pmid:21747205
|
Mahoney DJ et al. |
TSG-6 inhibits osteoclast activity via an autocrine mechanism and is functionally synergistic with osteoprotegerin. |
2011 |
Arthritis Rheum. |
pmid:21162099
|
Nahidi L et al. |
Osteoprotegerin in pediatric Crohn's disease and the effects of exclusive enteral nutrition. |
2011 |
Inflamm. Bowel Dis. |
pmid:20848544
|
Čolović M et al. |
FGF-R3 and OPG expression in patient with multiple myeloma following systemic sclerosis: case report and review of the literature. |
2011 |
Int. J. Hematol. |
pmid:21207214
|
Hashiguchi D et al. |
Mineral trioxide aggregate solution inhibits osteoclast differentiation through the maintenance of osteoprotegerin expression in osteoblasts. |
2011 |
J Biomed Mater Res A |
pmid:21171155
|
Li JY et al. |
Ovariectomy disregulates osteoblast and osteoclast formation through the T-cell receptor CD40 ligand. |
2011 |
Proc. Natl. Acad. Sci. U.S.A. |
pmid:21187391
|
Watkins M et al. |
Osteoblast connexin43 modulates skeletal architecture by regulating both arms of bone remodeling. |
2011 |
Mol. Biol. Cell |
pmid:21346198
|
Lau CP et al. |
Pamidronate, farnesyl transferase, and geranylgeranyl transferase-I inhibitors affects cell proliferation, apoptosis, and OPG/RANKL mRNA expression in stromal cells of giant cell tumor of bone. |
2011 |
J. Orthop. Res. |
pmid:20886653
|